Silence Therapeutics amends 8-K to disclose $1.28 million separation benefits for ex-CFO Tooman

• Silence Therapeutics filed an amended Form 8-K to update executive-compensation disclosure tied to former CFO Craig Tooman’s December 14, 2025 departure.
• The July 10, 2026 separation agreement sets cash benefits of USD 1.28 million, including USD 655,000 salary continuation and a USD 250,000 severance payment.
• It also provides a USD 283,746.03 bonus payment, USD 46,896.48 healthcare premium reimbursement, USD 40,000 legal-fee reimbursement, and up to USD 20,000 for tax-provider fees.
• Equity terms include limited continued vesting, longer option exercise windows, and potential vesting acceleration on a change of control within 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silence Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-306251), on July 16, 2026, and is solely responsible for the information contained therein.